Precision prime editing of TP53 mutations for functional tumor suppression in colorectal cancer.
Prime editing precisely corrects TP53 mutations without toxic DNA breaks, targeting one of cancer's most common and stubborn mutations.
This review/primary research hybrid in Biochem Biophys Res Commun examines the application of prime editing to restore TP53 tumor suppressor function in colorectal cancer, leveraging the base-change precision of prime editors to correct TP53 hotspot mutations without inducing DSBs or requiring template DNA. The approach targets one of the most prevalent and difficult cancer mutations across all cancer types.
What the study was
- Study design
- review_with_experimental_data
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Biochem Biophys Res Commun
Why it surfaced
TP53 is the most frequently mutated gene in cancer with no approved direct therapeutic correction; prime editing offers a more precise and safer route than previous CRISPR; colorectal cancer represents a major global cancer burden; relevant to precision oncology watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.